206 related articles for article (PubMed ID: 33142288)
1. Real-World Comparison of Elobixibat and Lubiprostone Treatment in Patients with Chronic Constipation: A Propensity Score-Matched Analysis.
Eguchi T; Yoshizaki T; Ikeoka S; Takagi M; Fujinami M; Matsuda T; Yamaguchi T; Nonaka T; Amioka S; Katayama N; Inoue K; Matsumoto M; Momose K; Sako T; Noda M; Morisawa T; Okada A
Dig Dis; 2021; 39(4):341-350. PubMed ID: 33142288
[TBL] [Abstract][Full Text] [Related]
2. Safety of elobixibat and lubiprostone in Japanese patients with chronic constipation: a retrospective cohort study.
Ooba N; Takahashi Y; Nagamura M; Takahashi M; Ushida M; Kawakami E; Kimura M; Sato T; Tokuyoshi J; Miyazaki C; Shimada M
Expert Opin Drug Saf; 2021 Dec; 20(12):1553-1558. PubMed ID: 34281471
[TBL] [Abstract][Full Text] [Related]
3. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial.
Nakajima A; Seki M; Taniguchi S
J Gastroenterol; 2018 Apr; 53(4):525-534. PubMed ID: 28840422
[TBL] [Abstract][Full Text] [Related]
4. Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study.
Kamei D; Kamei Y; Nagano M; Mineshima M; Nitta K; Tsuchiya K
BMC Gastroenterol; 2020 Jan; 20(1):26. PubMed ID: 32005162
[TBL] [Abstract][Full Text] [Related]
5. Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.
Kawada K; Ohta T; Fukuda H; Hayashi T; Tanaka K; Imai T; Morita Y; Miyamura M
Ann Hematol; 2020 Oct; 99(10):2429-2436. PubMed ID: 32839869
[TBL] [Abstract][Full Text] [Related]
6. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial.
Kumagai Y; Amano H; Sasaki Y; Nakagawa C; Maeda M; Oikawa I; Furuie H
Br J Clin Pharmacol; 2018 Oct; 84(10):2393-2404. PubMed ID: 29959787
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan.
Nakajima A; Taniguchi S; Kurosu S; Gillberg PG; Mattsson JP; Camilleri M
Neurogastroenterol Motil; 2019 May; 31(5):e13571. PubMed ID: 30793431
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
9. Effects of Elobixibat in Patients with Diabetes and Concomitant Chronic Constipation: an 8-week, Prospective, Single-center, Single-arm Study.
Hishida Y; Nagai Y; Tsukiyama H; Nakamura Y; Nakagawa T; Ishizaki S; Tanaka Y; Sone M
Adv Ther; 2022 Sep; 39(9):4205-4217. PubMed ID: 35867276
[TBL] [Abstract][Full Text] [Related]
10. New pharmacological treatment options for chronic constipation.
Corsetti M; Tack J
Expert Opin Pharmacother; 2014 May; 15(7):927-41. PubMed ID: 24661106
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors for Adverse Events in Patients with Chronic Constipation Following Lubiprostone Administration.
Eguchi T; Yoshizaki T; Takagi M; Ikeoka S; Hashimura H; Okamoto N; Matsumoto M; Matsuda T; Miura T; Momose K; Otsuka T; Morisawa T; Okada A
Dig Dis; 2021; 39(1):10-15. PubMed ID: 32450563
[TBL] [Abstract][Full Text] [Related]
12. Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Li F; Fu T; Tong WD; Liu BH; Li CX; Gao Y; Wu JS; Wang XF; Zhang AP
Mayo Clin Proc; 2016 Apr; 91(4):456-68. PubMed ID: 27046523
[TBL] [Abstract][Full Text] [Related]
13. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota.
Misawa N; Higurashi T; Takatsu T; Iwaki M; Kobayashi T; Yoshihara T; Ashikari K; Kessoku T; Fuyuki A; Matsuura T; Ohkubo H; Usuda H; Wada K; Naritaka N; Takei H; Nittono H; Matsumoto M; Honda A; Nakajima A; Camilleri M
Aliment Pharmacol Ther; 2020 Sep; 52(5):821-828. PubMed ID: 32687674
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of lubiprostone in patients with chronic constipation.
Barish CF; Drossman D; Johanson JF; Ueno R
Dig Dis Sci; 2010 Apr; 55(4):1090-7. PubMed ID: 20012484
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Elobixibat in Parkinson's Disease with Chronic Constipation: CONST-PD Study.
Hatano T; Oyama G; Shimo Y; Ogaki K; Nishikawa N; Nakamura R; Tsunemi T; Ogawa T; Eguchi H; Daida K; Kurita N; Ueno SI; Fukae J; Sako W; Shiina K; Nakajima S; Oji Y; Wakamori R; Saiki S; Nishioka K; Okuzumi A; Taniguchi D; Takeshige-Amano H; Fuse A; Nakajima A; Kano M; Kamo H; Yamashita Y; Shindo A; Yanagisawa N; Hattori N
Mov Disord Clin Pract; 2024 Apr; 11(4):352-362. PubMed ID: 38264844
[TBL] [Abstract][Full Text] [Related]
16. Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake.
Ozaki A; Kessoku T; Kasai Y; Takeda Y; Okubo N; Iwaki M; Kobayashi T; Yoshihara T; Honda Y; Fuyuki A; Higurashi T; Ishiki H; Taguri M; Oyamada S; Kobayashi N; Nakajima A; Ichikawa Y
Oncologist; 2021 Oct; 26(10):e1862-e1869. PubMed ID: 34180099
[TBL] [Abstract][Full Text] [Related]
17. Comparative profiles of lubiprostone, linaclotide, and elobixibat for chronic constipation: a systematic literature review with meta-analysis and number needed to treat/harm.
Rao SS; Manabe N; Karasawa Y; Hasebe Y; Nozawa K; Nakajima A; Fukudo S
BMC Gastroenterol; 2024 Jan; 24(1):12. PubMed ID: 38166671
[TBL] [Abstract][Full Text] [Related]
18. Elobixibat for the treatment of constipation.
Chedid V; Vijayvargiya P; Camilleri M
Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):951-960. PubMed ID: 30204504
[TBL] [Abstract][Full Text] [Related]
19. Lubiprostone for the treatment of functional constipation in children.
Hyman PE; Di Lorenzo C; Prestridge LL; Youssef NN; Ueno R
J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):283-91. PubMed ID: 24048162
[TBL] [Abstract][Full Text] [Related]
20. Evaluation and Comparison of Daiokanzoto and Lubiprostone for Constipation: A Retrospective Cohort Study.
Yoshida A; Hirose T; Kuroda A; Mitsuoka M; Shinoda Y; Mori K; Kawachi Y; Tanaka K; Takeda A; Sugiyama T; Yoshimura T
Biol Pharm Bull; 2019; 42(5):680-684. PubMed ID: 31061310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
